VPM
ELTX icon

Vanguard Portfolio Management’s Elicio Therapeutics ELTX Stock Holding History

Vanguard Portfolio Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Buy
+88,905
New +$893K ﹤0.01% 3089

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $751B AUM 15.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

Vanguard Portfolio Management's ELTX Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 88,905 shares worth $348K. The stake represents ﹤0.01% of the portfolio and ranks #3089 among its holdings.

37 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Vanguard Portfolio Management held 88,905 shares of Elicio Therapeutics worth $348K as of Q2 2026.
  • Elicio Therapeutics was a new Vanguard Portfolio Management position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #3089 holding.
  • 37 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.